drugset / Trial / NCT06329570

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

NCT06329570

Phase 1/2 Recruiting 10 enrolled NaviFUS Corporation NaviFUS US LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV represents the physician's best choice for the standard of care (SoC) in rGBM after previous treatment with surgery (if appropriate), standard radiotherapy with temozolomide chemotherapy, and with adjuvant temozolomide.

Timeline

Start
2024-10-22
Primary completion
2027-12-31
Completion
2028-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 10 mg/kg Intravenous
Background Lumason Diagnostic / imaging agent 0.1 unknown